Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis

Xinhui Hu,Hong Ding,Qing Wei,Ruoxin Chen,Weiting Zhao,Liqiong Jiang,Jing Wang,Haifei Liu,Jingyuan Cao,Hong Liu,Bin Wang
DOI: https://doi.org/10.1080/0886022x.2024.2302407
IF: 3.222
2024-01-12
Renal Failure
Abstract:Background Arteriovenous fistula (AVF) dysfunction is a common complication in patients undergoing maintenance hemodialysis (MHD). Elevated serum levels of fibroblast growth factor 21 (FGF21) are associated with atherosclerosis and cardiovascular mortality. However, its association with vascular access outcomes remains elusive. The present study evaluated the relationship of serum FGF21 levels with AVF dysfunction and all-cause mortality in patients undergoing MHD.
urology & nephrology
What problem does this paper attempt to address?